At a glance
ClinicalIndex Comparison RecordPhase 2Active· 214 enrolled
Drug / intervention
ND0612drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating ND0612 for Parkinson's Disease. Active but no longer recruiting, targeting 214 participants across 57 sites in 9 countries.
Detailed Summary
This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a continuous SC infusion in subjects with advanced Parkinson's Disease (PD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesAustria, Czechia, France, Germany, Israel, Italy, Poland, Spain, United States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
First PostedApr 2016
Enrollment StartMay 2016
Primary CompletionSep 2019
TodayJul 2026
Study CompletionFeb 2027
First PostedApr 1, 2016
Enrollment StartMay 4, 2016
Primary CompletionSep 9, 2019
Study CompletionFeb 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.3 years ago
Interventions
ND0612drug
ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system